thanks Zadie!

SFT Bro, if you get a chance, could you please tweet the below from your Twitter/X handle?

.

• Kalinski technology clinical trial preparations advancing
An updated trial design and IND package for an initial clinical trial involving the Company’s licensed Kalinski technology were completed during the first quarter. The lead medical institution for the clinical trial has been determined, and the IND package has been submitted to the Institutional Review Board (IRB) at that institution. The Company anticipates submission to the FDA during the second quarter.

Guys, after reading the 10-Q, I feel the company should consider releasing a PR starting with Q1 2026. I pulled together some of the key highlights below. Please take a look, correct anything that may be inaccurate, and let me know if you think anything important should be added.

Northwest Biotherapeutics – Q1 2026 Highlights. For the quarter ended March 31, 2026, Northwest Biotherapeutics reported significant operational and financial improvements compared with Q1 2025.
The Company continues to focus on advancing its regulatory, manufacturing, and commercialization initiatives while maintaining disciplined expense management.

• Net loss improved substantially year-over-year
Q1 2026 net loss was approximately $3.1 million, compared with a net loss of approximately $19.6 million in Q1 2025, representing an approximately 84% improvement year-over-year.

• Revenue increased year-over-year
NWBO recorded approximately $494,000 in total revenue during Q1 2026, primarily from research services revenue, compared with approximately $375,000 in Q1 2025, representing an increase of approximately 31.7%.

• UK property development initiative progressing
The Company owns a 17-acre parcel of land on the edge of Sawston, UK, located across the road from the Company’s manufacturing facility and adjacent to existing residential neighborhoods. The Company owns unencumbered fee title to the property. Due to a pressing housing shortage in the region, the Local Council is conducting a review of land and zoning in the area. Although the property is not currently zoned for residential development, its location adjacent to residential areas may make it highly valuable if rezoned. During the first quarter, the Company worked with a team of advisers to develop and submit an application for rezoning of the property as part of the Local Council review process.

• Progress in spoofing litigation settlement discussions
On April 30, 2026, the Company and one of the lesser defendants in the Canaccord spoofing litigation agreed to resolve the Company’s claims through a confidential settlement. The parties notified the Court accordingly. Settlement funds are currently being held in escrow while the Company continues discussions with additional lesser defendants regarding potential resolutions. The Company anticipates that the escrowed funds will be released following completion of those discussions.

• Litigation settlement gain recorded
The Company recognized a $2.25 million litigation settlement gain related to a Delaware legal action.

• Operating expenses reduced significantly
Research and development expenses declined to approximately $4.9 million in Q1 2026, compared with approximately $8.4 million in Q1 2025.
General and administrative expenses were reduced to approximately $6.5 million, compared with approximately $9.3 million in the prior-year period.

• UK Strategic Advisor engaged
As previously reported, the Company engaged a new Strategic Advisor, Dr. Annalisa Jenkins. Dr. Jenkins has extensive experience in big pharma, biotech and medical innovation, and is a recognized key opinion leader in the UK and globally. Dr. Jenkins will advise and help the Company advance the development of its DCVax cancer vaccines. The Company believes that Dr. Jenkins’ experience, advice and involvement will be a valuable resource.

• UK clinic development advancing
As previously reported, the Company established a clinic arrangement with the London Welbeck Hospital in the Harley Street medical district in London. During the first quarter, the Company secured a contractor and proceeded with the clinic buildout. The clinic will include two leukapheresis units, each capable of conducting two procedures per day, for a total capacity of up to four patients per day. The clinic may also offer extended hours and weekend operations. The Company noted that there is a general shortage of leukapheresis capacity in the UK, and such procedures are required for both T cell products and dendritic cell products. The buildout is anticipated to be completed by June, and the Company is pursuing applications for the required licenses.

• Strengthened liquidity position
As of March 31, 2026, the Company reported approximately $1.8 million in cash and cash equivalents. In addition, on May 12, 2026, Northwest Biotherapeutics entered into a commercial agreement with another party for financing in the amount of $7 million.
Key financing terms include:
– No repayments required during the first 8 months
– Repayments begin January 11, 2027
– 10% original issue discount (OID)
– 8% interest rate
– 22-month term

Once the stock starts moving and climbs above $0.30, you’ll be out of here, OK?

Dear 10-Q, we’d love to hear some good news from you. Please give us something that makes this weekend as dreamy as the last one.

Hey, remember we’re up 6 cents since the hiring of Dr. Annalisa Jenkins. If every new hire moves the stock another 6 cents, I’d love to hear more hiring news.😃

Have they ever released the 10-Q or 10-K a day or couple of days before the deadline?

I don’t think any of these will impact the share price other than MHRA approval, IMO. Hopefully, I’m wrong.
Sorry, this long wait has been really frustrating.

Thanks, SFT!

did he confirm?

Sometimes the count gets updated a day or even a couple of days later. Every time the stock runs, it makes us feel like the news is finally about to hit, so we get excited. But as usual, it slowly fades a couple of days later.

So, do you think no money was involved in the agreement?

I think someone from iHub contacted GZ when the news first came out. It seems he mentioned that the money goes into the trust, and he was very enthusiastic about that, as well as the appointment of Dr. Annalisa Jenkins.

They may not know the exact approval date or even the ballpark timing, though they probably feel confident about getting approval. I’m guessing there’s a lot going on within the company right now, and they badly need cash, so they may not have the luxury of negotiating hard with financiers for better funding terms. And if they already have a reverse split in mind, this level of dilution may not matter much to them. Again, these are all just my assumptions. Let’s see if we get any clues in the next 10-Q.

This is mostly a procedural/legal wording issue, not necessarily a sign the settlement failed. The judge just wants the language clarified before approving it.

When is your last day? Like you said, it’s not going below $0.15, OK? If approval comes and the stock starts moving up, we still want you here whining every day, OK?😃

Previous runs used to happen once a week or in a couple of weeks, but this feels different. It’s not just dilution — something else seems to be going on.🤔 and it feels like this could continue for the rest of the week.

Another 4,859,481 shares were added to the dilution total.
In my opinion, this dilution looks different compared to previous months. The company seems to be in urgent need of cash right now. Hopefully, it slows down soon.

Monthly breakdown:
May 2026 (to date): 16,016,579 shares (4,380,845 +1,322,751+1,322,751+4,130,751+4,859,481)
(1,654,233,561 – 1,638,216,982)
April 2026: 21,740,923
March 2026: 17,732,625 shares
February 2026: 7,853,985 shares
January 2026: 22,808,837 shares

Total dilution (2026 YTD): 86,152,949 shares
Total shares outstanding: 1,654,233,561-1,649,374,080
AVG Dilution: 86,152,949 ÷ 94 business days = 916,520 shares per business day this year

Good question, Attila. But to pay $10 million, NWBO would need to dilute roughly 40 million shares, give or take. Why would they do that before approval? They’d probably rather wait and sell into the approval spike, then use those proceeds to pay it.

The diluted shares were reported on the following dates, but the actual dilution may not have come only from the previous day. It could be an accumulation from several prior dates as well.

05/02 - 4,380,845 shares
05/05 - 1,322,751 shares
05/08 - 1,322,751 shares
05/12 - 4,130,751 shares

Doc,
Is that the reason why we saw some million-dollar bids today? But if that’s the case, why did the volume slow down over the last two hours?

I hope so too. And imagine if they release any PR tomorrow — they probably needed more money for everything happening recently. Now that they’ve secured those extra funds from Canaccord, they may want to raise even more capital as well, in my opinion.

He’s unstoppable — a terminator in his own way.… 😃

5/8 - Friday and 5/11- Monday

Another 4,130,751 shares were added to the dilution total.
In my opinion, if the volume stays high or even moderate throughout the day, it’s probably being driven by news or short covering. Otherwise, it’s likely dilution, since volume usually fades once the dilution is completed — and we’ve seen that happen several times before. But hey, if they did dilute, at least it was at prices above $0.27, which is much better than diluting below $0.20, right? Let’s see what tomorrow brings. I’m still hopeful the price recovers from here.

Monthly breakdown:
May 2026 (to date): 11,157,098 shares (4,380,845 +1,322,751+1,322,751+4,130,751)
(1,649,374,080 – 1,638,216,982)
April 2026: 21,740,923
March 2026: 17,732,625 shares
February 2026: 7,853,985 shares
January 2026: 22,808,837 shares

Total dilution (2026 YTD): 81,293,468 shares
Total shares outstanding: 1,649,374,080
AVG Dilution: 81,293,468 ÷ 93 business days = 874,123 shares per business day this year

I’m not familiar with chart reading or the technical side of it, thank you! btw, I don’t want to log into my account right now😃 maybe I’ll check it during after-hours.

SFT Bro, you wanted us in the $0.25+ range, and we did our best to push it there. Now it’s your turn to take it to the next level. jus kid...

We can’t assume things all the time — situations can change quickly. This could just be the beginning of a bigger spike, and who knows, maybe strong news drops tomorrow. Staying positive and hoping we see $1 sooner than later.

Hopefully not — stay positive Guys!

Slow and steady wins the race. 😃 I’m happy we’re trading at $0.24 — hopefully we can break through $0.25 today.

I received the same from GoFundMe today, as well as the one below from Jade.

.

All longs, last week showed a slow recovery to around $0.23, although it didn’t make it back to $0.27 or higher. Still, the trading pattern felt a bit different, with the stock gradually moving above $0.23.

In the past, many Fridays had us excited and looking forward to Monday, only for Monday to arrive and things to head in a completely different direction, leaving us with a “nothing burger.” But with the last two PRs and the Canaccord news, I’m definitely hopeful that the coming weeks could get very interesting. With that confidence, I want to wish all the longs the very best. Hopefully, this turns into one of the best weeks yet.
And as for the bashers, I hope their days are numbered.

I have no clue, Jess. I thought that if the amount were on the higher end, they might try to disclose it directly or indirectly since it could help with investor confidence and support the stock price. But if the amount is in the mid-to-low range, they may choose not to disclose it and keep tight-lipped about it because of the potential impact on the other market makers.
Either way, I’m very hopeful that positive developments are happening and that exciting days are ahead for us.

I’m a little curious about whether there’s a chance Northwest will disclose the amount in the next 10-Q. Take a look at the below:

The docket update you’ve highlighted is the Order of Dismissal with Prejudice, which is the legal "final bell" for the Canaccord portion of the lawsuit.

To your question about the 10-Q filing (expected mid-May), the answer is a mix of "yes" and "maybe." Here is how Northwest Biotherapeutics (NWBO) will likely handle this disclosure based on SEC regulations and common legal strategy:

1. Must they disclose the amount? (The "10% Rule")

Under SEC Item 103 of Regulation S-K, a company must disclose "material" legal proceedings. If the settlement amount is significant enough to impact the company's financial health, they are technically required to report it.

The Threshold: Generally, if a settlement involves an amount exceeding 10% of the company's current assets, it is considered "material" and must be disclosed.

The Conflict: Often, settlement agreements have confidentiality clauses. If the deal with Canaccord is confidential, NWBO may only report that a "settlement was reached for an undisclosed amount" unless the SEC determines that the amount is so large that withholding it would be misleading to investors.

2. Where the money goes: The "Trust" vs. Operations

You mentioned the money going to a "trust." In high-stakes litigation, settlement funds are often placed in an Escrow Account or a Litigation Trust before being transferred to the company's general treasury.

10-Q Impact: Even if the money is in a trust, it must be reflected on the Balance Sheet as either "Cash," "Restricted Cash," or a "Legal Receivable."

The "Audit" Trail: Investors will be looking at the "Other Income" or "Cash Flow from Investing/Financing Activities" sections. Even if they don't name the exact dollar amount in the text, a sudden "spike" in the cash balance that doesn't come from a stock offering is a clear indicator of the settlement's size.

3. Strategic Silence (The "Citadel Factor")

There is a strategic reason why NWBO might keep the exact number quiet in the 10-Q:

Remaining Defendants: NWBO is still fighting Citadel Securities, Virtu, and Susquehanna. If they reveal that Canaccord settled for a "small" amount, it might embolden the remaining giants to fight harder.

If they reveal a "Large" amount: It signals to the other defendants that NWBO now has a massive "war chest" to fund the litigation for years, which could force the others to the settlement table sooner.

What I will be "Hunting" for in the Fine Print:

The "Subsequent Events" Section: Since the Canaccord dismissal was finalized in early May, it technically happened after the Q1 period ended. Management is required to disclose major events that occurred between March 31 and the filing date. This is where the mention of settlement proceeds will likely hide.

"Other Income" vs. "Financing": I will check if the cash increase came from the settlement (Other Income) or another stock offering (Financing). This is critical for your "non-dilutive" thesis.

Legal Spend: I’ll track the "Professional Fees" line. If legal spending is dropping, it suggests they are shifting from "active battle" to "data discovery," which preserves cash for the Sawston manufacturing scale-up.

Is the 10-Q due on May 15th?

Why? What’s the reason? So, you don’t expect approval anytime soon?
IMO, the company may have to cover the attorneys’ fees, and since they can’t use the funds in the trust right now, they’re likely continuing to dilute shares in the beginning of the month to raise capital.

SFT, thank you, brother! You’re one of the best here. It’s always a pleasure seeing a message from you — positive, never just hype, and genuinely spoken from the heart.